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Background: When developing a prediction model for survival data it is essential to validate its performance in
external validation settings using appropriate performance measures. Although a number of such measures have
been proposed, there is only limited guidance regarding their use in the context of model validation. This paper
reviewed and evaluated a wide range of performance measures to provide some guidelines for their use in practice.
Methods: An extensive simulation study based on two clinical datasets was conducted to investigate the
performance of the measures in external validation settings. Measures were selected from categories that
assess the overall performance, discrimination and calibration of a survival prediction model. Some of these
have been modified to allow their use with validation data, and a case study is provided to describe how
these measures can be estimated in practice. The measures were evaluated with respect to their robustness
to censoring and ease of interpretation. All measures are implemented, or are straightforward to implement,
in statistical software.
Results: Most of the performance measures were reasonably robust to moderate levels of censoring. One
exception was Harrell’s concordance measure which tended to increase as censoring increased.
Conclusions: We recommend that Uno’s concordance measure is used to quantify concordance when there are
moderate levels of censoring. Alternatively, Gönen and Heller’s measure could be considered, especially if censoring
is very high, but we suggest that the prediction model is re-calibrated first. We also recommend that Royston’s D is
routinely reported to assess discrimination since it has an appealing interpretation. The calibration slope is useful for
both internal and external validation settings and recommended to report routinely. Our recommendation would be
to use any of the predictive accuracy measures and provide the corresponding predictive accuracy curves. In addition,
we recommend to investigate the characteristics of the validation data such as the level of censoring and the
distribution of the prognostic index derived in the validation setting before choosing the performance measures.
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Prediction models are often used in the field of health-
care to estimate the risk of developing a particular health
outcome. These prediction models have an important
role in guiding the clinical management of patients and
monitoring the performance of health institutions [1, 2].
For example, models have been developed to predict the* Correspondence: shafiq@isrt.ac.bd
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and to predict the risk of developing cardiovascular
disease within the next 10 years [3, 4]. Given their
important role in health research, it is essential that the
performance of a prediction model is evaluated in data
not used for model development, using appropriate stat-
istical methods [5, 6]. This model evaluation process is
generally termed ‘model validation’ [7, 8]. The general
idea of validating a prediction model is to establish that
it performs well for new patients. Different types of valid-
ation process have been discussed in the literature [5–8].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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single dataset (randomly or based on time) into two parts,
one of which is used to develop the model and the other
used for validation, (internal or temporal validation) and
(ii) validating the model using a new dataset collected
from a relevant patient population in different centres
(external validation). Of the two approaches, external
validation investigates whether a prediction model is
transportable (or generalisable) to new patients.
When validating a prediction model, the predictive
performance of the model is commonly addressed by
quantifying: (i) the ‘distance’ between the observed and
predicted outcomes (overall performance); (ii) the ability
of the model to distinguish between low and high risk
patients (discrimination); (iii) the agreement between the
observed and predicted outcomes (calibration) [8].
Performance measures based on these concepts are well
established for risk models for binary outcomes [1, 9, 10],
but that is not the case for risk models for survival out-
comes (survival prediction models) where censoring
complicates the validation process [6].
Several performance measures have been suggested for
use with survival prediction models. However, a few of
these are not appropriate for use with validation data
without modification. Also, some require specification of
a clinically appropriate time-point or region to match
the aims of the validation study. Some of these perform-
ance measures have been reviewed previously [11–17],
although only two of the reviews were in the context of
model validation. These were Hielscher et al. who
reviewed ‘overall performance’ measures, and Schmid and
Potapov who reviewed discrimination measures [12, 16].
Consequently, it is still unclear which performance mea-
sures should be routinely used in practice when validating
survival prediction models using external data.
A good performance measure should be unbiased in
the presence of censoring in the validation data. If this
were not the case, the level of censoring would affect the
evaluation of model performance and a high level of
censoring might lead to an over-optimistic verdict
regarding the performance of the prediction model. In
addition, a good measure should be straightforward to
interpret and, ideally, should be easy to implement or
available in widely used software.
The aim of this paper is to review all types of performance
measures (overall performance, discrimination and
calibration) in the context of model validation and to
evaluate their performance in simulation datasets with
different levels of censoring and case-mix. Where
necessary, measures have been modified to allow their
use with validation data and a case study is provided
to describe how these measures can be estimated in
practice. Recommendations are then made regarding
the use of these measures in model validation.Methods
Data
Two datasets, which have previously been used to
develop clinical prediction models, were used as the
basis of the simulation study. They differ with respect to
event rates, level of censoring, types of predictors and
amount of prognostic information.
Breast cancer data
This dataset contains information on 686 patients diag-
nosed with primary node positive breast cancer from the
German Breast Cancer Study [18]. The outcome of
interest is recurrence-free survival time and the dataset
contains 299 (44%) events. The median follow-up time is
3 years. The predictors are age, number of positive
lymph nodes, progesterone receptor concentration,
tumour grade (1–3), and hormone therapy (yes/no).
These data have been analysed previously by Sauerbrei
and Royston and their Model III was used as the basis
for simulation [19]. That is, the continuous predictors
were all transformed using fractional polynomials (FPs)
and tumour grade was dichotomised (1/2–3). Number of
positive lymph nodes and progesterone receptor concen-
tration were each modelled using one FP term whereas
age was modelled using two FP terms.
Hypertrophic cardiomyopathy data
This dataset contains information on a retrospective
cohort of 1504 patients with hypertrophic cardiomyop-
athy (HCM) from a single UK cardiac centre [20]. The
outcome of interest is sudden cardiac death or an
equivalent event, i.e., a composite outcome and the dataset
contains just 84 (6%) events. The median follow-up
time is over 6 years. The predictors of interest are
age, maximal wall thickness, left atrial diameter, left
ventricular outflow gradient, family history of sudden
cardiac death (yes/no), non-sustained ventricular
tachycardia and unexplained syncope (yes/no). The
prediction model produced by O’Mahony et al. was
used as the basis for simulation [20]. In particular,
maximal wall thickness was modelled using linear and
quadratic terms.
Prediction models for survival outcomes
Prediction models for survival outcomes are com-
monly developed using the Cox proportional hazards
model and hence this model was used in the simula-
tions [5, 21]. The Cox model
h tjxð Þ ¼ h0 tð Þ exp ηð Þ
models the hazard h(t|x) at time t as a product of a
nonparametric baseline hazard h0(t) and the exponential
of the prognostic index η = β1x1 +… + βpxp = β
Tx. The
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regression coefficients β1, …, βp providing weights. The
predictive form of this model can be written in terms of
the survival function as
S tjxð Þ ¼ S0 tð Þ exp ηð Þ
where S(t|x) is the probability of surviving beyond time t
given predictors x, and S0(t) is the baseline survivall
function at time t, where S0(t) = exp[−∫0
t h0(u)du]. To
make predictions at a specific time-point τ, one requires
estimates β^ and S^0 τð Þ.
Performance measures for survival prediction models
Measures were selected for investigation on the basis of
their performance in previous reviews [11–16], their
ease of interpretation, and their availability, or ease of
implementation, in statistical software. The selected
performance measures are now described in the context
of model validation. All measures were implemented in
Stata using either built-in or user-written routines [22].
Measures of overall performance
Six measures of ‘overall performance’ were selected, of
which four are based on predictive accuracy and two on
explained variation [14]. These ‘R2-type’ measures typic-
ally take values between 0 and 1, though negative values
may be possible in validation data if the prediction
model is out-performed by the null model that has no
predictors. This issue is discussed later.
The measures based on predictive accuracy were Graf
et al’s R2 measure and its integrated counterpart [23],
Schemper and Henderson’s R2 measure [24], and a
modified version of the latter based on Schmid et al.
[25]. The measures based on explained variation were
Kent and O’Quigley’s R2PM [26], and Royston and
Sauerbrei’s R2 version of their separation statistic D
[27]. Nagelkerke’s R2 measure was not considered due
to its known poor performance in the presence of
censoring [26, 28].
Graf et al’s R2BS and R
2
IBS
The R2BS measure proposed by Graf et al. is based on
quantifying prediction error at a time-point τ using a
quadratic loss function [21]. Specifically, RBS
2 (τ) = 1 −
BS(τ|X)/BS(τ) where
BS τjXð Þ ¼
Z
X
E I T > τð Þ− S ̂ τjXð Þ
 2 
dFX Xð Þ
is the prediction error at time τ for the prediction model
and I(T > τ) is the individual survival status at this time-
point. Similarly, BS(τ) is the prediction error for the null
model at the same time-point, and is based on the sur-
vival function Ŝ τð Þ from the null model. The integratedversion, RIBS
2 (τ), is defined in a similar way to RBS
2 (τ) but
involves integrating both BS(t|x) and BS(t) over the
range [0, τ].
The calculation of prediction errors for both of these
models in validation data requires estimates of the corre-
sponding baseline survival functions. This, however, is
rarely provided by model developers [6]. One solution
might be to estimate these survival functions by re-
fitting the Cox model with the PI as the sole predictor in
the validation data. This is the approach that we took
when calculating R2BS and R
2
IBS, and the R
2
SH and R
2
S mea-
sures described below.
Schemper and Henderson’s R2SH and Schmid et al’s R
2
S
The R2 measure proposed by Schemper and Henderson
(denoted here by R2SH) is similar to Graf et al’s R
2
IBS but
is based on an absolute loss function [24]. This loss
function was chosen to reduce the impact of poorly pre-
dicted survival probabilities, which are likely to occur in
the right tail of the survival distribution. Specifically,
RSH
2 (τ) = 1 −D(τ|x)/D(τ), where
D τjxð Þ ¼ 2
Z τ
0
E S tjXð Þ 1−S tjXð Þð Þ½ f tð ÞdtW τð Þ
is the prediction error at time τ for the prediction model
and W(τ) = 1/∫0
τf(t)dt is a weight function to compensate
for the measure being defined only on (0, τ). Similarly,
D(τ) is the prediction error for the null model.
Schmid et al. prove that Schemper and Henderson’s
estimator of D(τ|x) and D(τ) is not robust to model mis-
specification and suggest an improved estimator [25].
We estimated a summary measure, denoted by R2S, based
on this estimator.
Kent and O’Quigley’s R2PM
Kent and O’Quiqley’s proposed their R2PM measure for
the Cox model based on the definition of R2 for linear
regression [26]. That is,
R2PM ¼
Var ηð Þ
Var ηð Þ þ σ2
seeks to quantify the proportion of variation in the out-
come explained by the predictors in the prediction
model, where σϵ
2 ≅ π2/6 is the variance of the error term
in an equivalent Weibuill model [13].
This measure does not use the observed survival times
directly in its calculation and instead relies on the pre-
diction model being correctly specified. As a result, R2PM
could be misleading if an apparent strong relationship
between the outcomes and predictors in development
data is not reproduced in validation data. To overcome
this deficiency, we suggest re-calibrating the prediction
model to the validation dataset before calculation of
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R2PM and is described later.
Royston and Sauerbrei’s R2D
Royston and Sauerbrei’s R2D is similar to R
2
PM but is based
on the authors’ own D statistic, a measure of prognostic
separation described later. That is,
R2D ¼ D
2=κ2
D2=κ2þσ2 ,
where κ ¼ ﬃﬃﬃﬃﬃﬃﬃﬃ8=πp [27]. The ratio D2/κ2 is an estimator of
Var(η), provided that η is Normally distributed.
Measures of discrimination
Four measures of discrimination were selected, of which
three are based on concordance and one on prognostic
separation. Discrimination measures assess how well a
model can distinguish between low- and high- risk
patients, and concordance measures in particular quan-
tify the rank correlation between the predicted risk and
the observed survival times. Concordance measures usu-
ally take values between 0.5 and 1, where a value of 0.5
indicates no discrimination and a value of 1 indicates
perfect discrimination. The selected concordance mea-
sures were those of Harrell [29], Uno et al. [30], and
Gönen and Heller [31], and the selected prognostic separ-
ation measure was Royston and Sauerbrei’s D statistic [27].
Harrell’s CH
The concordance probability is the probability that of a
randomly selected pair of patients (i,j), the patient with
the shorter survival time has the higher predicted risk.
Formally,
C ¼ P ηi > ηjjTi < Tj
 
where ηi and ηj are the prognostic indices for patients i
and j, and Ti and Tj are the corresponding survival
times. Harrell’s estimator CH considers all usable pairs of
patients for which shorter time corresponds to an event
and estimates CH as the proportion of these pairs for
which the patient with the shorter survival time has the
higher predicted risk [31]. A modified version of this
estimator, CH(τ), restricts the calculation to include just
those patient pairs where Ti < τ and may provide more
stable estimates [29, 30]. This truncated version may also
be preferred if one were primarily interested in the
discrimination of a prediction model over a specified
period, for example within 5 years [20].
Uno et al’s CU
In the presence of censoring CH and CH(τ) are biased,
even under independent censoring, as they ignore patientpairs where the shorter observed time is censored [15, 32].
Due to this deficiency, Uno et al. [30] proposed a modified
estimator CU(τ) that uses weightings based on the prob-
ability of being censored. Furthermore, like CH(τ), the cal-
culation may also be restricted to include just those
patient pairs where Ti < τ. Uno et al. found that their esti-
mator was reasonably robust to the choice of τ, but noted
that the standard error of the estimate could be quite large
if τ were chosen such that there was little follow-up or few
events beyond this time point [29].
Gonen and Heller’s CGH
Gönen and Heller proposed an alternative estimator
CGH based on a reversed definition of concordance [30],
K ¼ P Ti < Tjjηi > ηj
 
;
which is the probability that of a randomly selected pair of
patients (i, j), the patient with the higher predicted risk has
the shorter survival time. To avoid bias caused by
censoring, their estimator is a function of the model
parameters and the predictor distribution and assumes
that the proportional hazards assumption holds.
As with R2PM, CGH does not use the observed event
and censoring times in its calculation and relies on the
prediction model being correctly specified [15]. There-
fore, we suggest re-calibrating the prediction model to
the validation dataset before calculating CGH.
Royston and Sauerbrei’s D
The D statistic is a discrimination measure that quantifies
the observed separation between subjects with low and
high predicted risk [27]. Specifically, D estimates κσ,
where σ is the standard deviation of the prognostic
index and κ ¼ ﬃﬃﬃﬃﬃﬃﬃﬃ8=πp . The scale factor κ enables D to
be interpreted as the log hazard ratio that compares
two equal-sized risk groups defined by dichotomising
the distribution of the patient prognostic indices at
the median value.
Measures of calibration
One calibration measure was selected, the commonly
used calibration slope proposed by van Houwelingen
[33], which is based on the analogous measure for binary
outcomes [34, 35].
Calibration slope
The calibration slope is simply the slope of the regres-
sion of the observed survival outcomes on the predicted
prognostic index [33]. It is estimated by fitting a Cox
model to new survival outcomes with the predicted
prognostic index, η ̂, as the sole predictor in the model
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Values of α ̂1 close to 1 suggest that the prediction
model is well calibrated. Moderate departures from 1
indicate that some form of model re-calibration may be
necessary. In particular, α ̂1≪1 suggests over-fitting in the
original data with predictions that may be too low for
low risk patients or too high for high risk patients.
A brief summary of the performance measures is given
in Table 1.
Results
Case study to illustrate the performance measures
A case study is now presented using the breast cancer
data in order to describe how the performance measures
may be evaluated in a validation setting. The dataset was
split randomly into two parts with two thirds of the data
used for model development and one third used for
model validation. A Cox model was fitted to the devel-
opment data using the same predictors as in Sauerbrei
and Royston’s Model III [19] and the predicted prognos-
tic index was calculated for all patients in the validation
data using the estimated regression coefficients β ̂ . The
values of all performance measures are shown in Table 2
with 95% confidence intervals estimated using the boot-
strap techniques based on 200 bootstrap samples. For
those measures that require specification of a time-point
τ, 3 years was deemed to be clinically appropriate. This
was also the median follow-up time.
The estimated prediction errors used to estimate R2BS and
R2IBS are shown in Fig. 1a. The errors for the prediction and
null models are similar for the first 12 months after which
the superiority of the prediction model is evident. The cor-
responding prediction errors used to estimate R2SH appear
similar in shape although the magnitude of the errors are
larger due to the use of an absolute loss function (Fig. 1b).
The prediction errors used to estimate R2S are almost indis-
tinguishable from those used to estimate R2SH (results not
shown). R2IBS, R
2
SH and R
2
S were estimated after averaging
the prediction errors over the first 3 years. As expected R2SH
and R2S are very similar, and both are slightly larger than
R2IBS. R
2
BS was estimated using just the prediction errors at
3 years in Fig. 1a. Its value is larger than that of R2IBS as the
separation between the prediction errors is close to its max-
imum at this time-point.
To estimate R2PM in the valids first re-calibrated for rea-
sons explained earlier. That is, the Cox model h tj η ̂ð Þ ¼ h0
tð Þ exp α η̂ð Þ was fitted to the validation data, where η ̂
is the predicted prognostic index calculated using the
regression coefficients estimated in the development
data. R2PM was then estimated using α ̂
2 Var η ̂ð Þ rather
than Var η ̂ð Þ . No such re-calibration is required to
estimate R2D since, unlike R
2
PM, it uses the observedsurvival outcomes in the validation data. The values
of R2PM and R
2
D are very similar and noticeably larger
than the measures based on predictive accuracy
(Table 2). We note that a naïve calculation (without
re-calibration) of R2PM would have produced a much
larger value of 0.292, which would have provided an
over-optimistic quantification of the model’s predictive
performance.
The concordance measures CH and CU were estimated
using all usable pairs in which shorter time corresponds
to an event, and CGH was estimated after re-calibrating
the prediction model to the validation data as described
above. The values of these 3 measures are all reasonably
similar and would lead to similar conclusions in practice
(Table 2). A naïve estimation of CGH (without re-
calibration) would have produced a much larger value of
0.696. Restricting the estimation of CH and CU by
censoring survival times in the validation data at 3 years
produces slightly higher values for both measures,
suggesting that the risk model has slightly better
discrimination when considering survival over just the
first 3 years. The D statistic suggests that the prediction
model provides a reasonably high amount of prognostic
separation (Table 2). Specifically, if one were to form
two risk groups of equal size in the validation data, then
the corresponding hazard ratio would be exp(0.998) = 2.71.
The calibration slope estimate of 0.76 (equal to the α ̂ esti-
mated during the re-calibration process above) suggests
that the prediction model has been slightly over-fitted. We
note that, in practice, one can detect and adjust for model
over-fitting during model development.
The selected measures all provide useful information.
R2IBS, R
2
SH, and R
2
S, provide a summary measure quantify-
ing the improvement in predictive accuracy offered by
the prediction model over the null model. The R2BS
measure is more appropriate if one is interested in
predictive accuracy at a specific time-point, which is
sometimes the case in practice. The prediction error
curves provide additional insight into the performance
of the prediction model at different time-points. R2PM
and R2D, which both quantify explained variation,
produced very similar values though calculation of R2PM
required a re-calibration of the prediction model. The
concordance measures CH, CU and CGH produced
similar estimates, though calculation of CGH required
the prediction model to be re-calibrated. Additionally, if
required, the calculation of CH and CU can be restricted
which may be appropriate if one wishes to quantify the
discrimination of a prediction model before a specified
time-point. Finally, the D statistic produces an intuitive
quantification of prognostic separation and the calibra-
tion slope provides a succinct indication of whether the
prediction model is over-fitted or not.
Table 1 Summary of the performance measures
Types of
Measures
Measures Characteristics Range and Interpretation Software
Overall Performance R2BS Assesses relative gain in predictive
accuracy quantified using at a specific
time point based on squared error
loss function.
Range: 0 to 1
Interpretation: % gain in predictive
accuracy at a single time point
relative to the null model.
Available in SAS and R
and easy to implement
in other software
R2IBS Same approach as R
2
BS but provides
a summary over a range of time period.
Range: same as R2BS Interpretation:
% gain in predictive accuracy over
a range of time period relative to
the null model.
Available in SAS and R and
easy to implement in other
software
R2SH Assesses relative gain in predictive
accuracy quantified based on absolute
error loss function. It is not robust to
model mis-specification.
Same as R2IBS Available in SAS and R and
easy to implement in other
software
R2S Modified version of R
2
SH which is
robust to model mis-specification.
Same as R2IBS Available in SAS and R
and easy to implement
other software
R2PM Measures the variation in the outcome
explained by the covariates in the model.
Assume that the model is correctly
specified. Requires re-calibration in
the validation data.
Range: 0 to 1
Interpretation: % of explained
variation by the model.
Easy to implement in
any software
R2D Measures the relative gain in prognostic
separation quantified by the D statistic.
Assume that the PI is normally distributed.
Range: 0 to 1
Interpretation: % of prognostic
separation explained by the model.
Available in Stata and
easy to implement in
other software
Discrimination CH Rank order statistic based on usable
pairs in which shorter time corresponds
to an event.
Range: 0.5 to 1
Interpretation: probability of correct
ordering for a randomly selected
pair of subjects.
Available in R and Stata
and easy to implement
in software
CU Rank order statistic based on usable pairs.
Inverse probability weighting is used to
compensate for censoring.
Same as CH. Available in R and easy
to implement in other
software
CGH Rank order statistic based on all patient
pairs. Assumes that Cox PH model is
correctly specified.Requires re-calibration
in the validation data.
Same as CH. Available in R and Stata and
easy to implement in other
software
D Quantifies the observed separation
between low and high risk groups.
Assumes that PI is normally
distributed.
Range: 0 to ∞
Interpretation: log hazard ratio between
two equal sized prognostic groups
fromed by dichotomising the PI
at its median..
Available in Stata and easy
to implement in other
software
Calibration Cal Slope Regression slope of the PI and assesses
the agreement between the observed
and predicted survival..
Range: −∞ to ∞
Interpretation: a value of 1 suggests
perfect calibration and a value much
lower than 1 suggest overfitting.
Easy to implement in
any software
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Following the case study, a simulation study was per-
formed to investigate how robust the measures are with
respect to both censoring and the characteristics of the
validation data. The simulation design is now described.
Simulation scenarios
The simulation study is based on the breast cancer and
HCM datasets described earlier. For both datasets, de-
velopment and validation datasets were generated by
simulating new outcomes based on a true model and
combining these with the original predictor values.
Models were fitted in the development data and theperformance measures estimated in the validation data.
Measures which require a choice of time-point τ (including
CH and CU) used 3 years for the breast cancer data and
5 years for the HCM data. These values were chosen as
they are close to the respective median follow-up times in
the original datasets and are conventional choices for sur-
vival data. In practice, the choice of time-point would be
clinically motivated and based on the underlying research
question.
The performance measures were investigated over a
range of scenarios to mimic real situations. For all simu-
lations, validation data were constructed to have one of
three different risk profiles (denoted low, medium, and
Table 2 Values of the performance measures estimated in the
breast cancer validation data
Measure Value (95% CI)
R2IBS(3) 0.107 (0.036 to 0.178)
R2SH (3) 0.130 (0.089 to 0.171)
R2S (3) 0.128 (0.090 to 0.167)
R2BS(3) 0.141 (0.033 to 0.250)
R2PM 0.194 (0.094 to 0.294)
R2D 0.192 (0.093 to 0.291)
CH 0.674 (0.622 to 0.726)
CU 0.666 (0.610 to 0.722)
CGH 0.659 (0.616 to 0.701)
CH(3) 0.685 (0.633 to 0.737)
CU(3) 0.676 (0.619 to 0.734)
D 0.998 (0.672 to 1.323)
Cal. Slope 0.764 (0.531 to 0.996)
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that, in practice, the characteristics of the patients in the
development and validation data may differ [36]. In par-
ticular, the event rate for patients in the validation data
may be higher or lower than that for patients in the de-
velopment data due to differences in case-mix.
Four levels of random censoring were considered for
the validation datasets (0, 20, 50, and 80%) which
combined with the risk profiles, results in a total of 12
validation scenarios for each clinical dataset. The devel-
opment datasets were generated with no censoring.
5,000 pairs of development and validation datasets were
generated for each scenario.Fig. 1 Prediction errors over time for the breast cancer risk model for: a) p
and R2BS; b) prediction error (based on an absolute loss function) for calculaGenerating new survival and censoring times
Survival times were generated using the Weibull distri-
bution as below
ts ¼ − log uð Þexp ηð Þ
 1
γ
where η and γ are the observed regression prognostic
indices and shape parameter respectively (both used
here as the proxy of the true values) and u is a uniformly
distributed random variable on (0, 1). For the breast can-
cer data, the prognostic indices and shape parameter
were obtained by fitting a Weibull proportional hazards
model using the same predictors as in Sauerbrei and
Royston’s Model III [19]. For the HCM data, the prog-
nostic indices were based on the regression coefficients
estimated by O’Mahony et al. [20] and just the shape
parameter was estimated using a Weibull model with
the prognostic index specified as an offset.
To introduce random censoring, additional Weibull dis-
tributed censoring times were simulated using tc = (−log(u)/
λ)1/γ where different choices of the scalar λ were used to
give different proportions of censoring. A subject was con-
sidered to be censored if their censoring time was shorter
than their survival time.
Generating validation data with different risk profiles
The three different risk profiles were created in the
validation data, by first splitting the patients into tertile
risk groups based on their true prognostic index η. It is
assumed that the first tertile group consists of low-risk
patients, the second medium risk, and the third high-rediction error (based on a quadratic loss function) for calculating R2IBS
ting R2SH
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data were created in the following way:
a) low risk profile: 80% of the patients were sampled
(without replacement) from the low-risk group, 50%
from the medium-risk group, and 20% from the
high-risk group;
b) medium risk profile: 50% of the patients were
sampled from the low-risk group, 50% from the
medium-risk group, and 50% from the high-risk
group;
c) high risk profile: 20% of the patients were sampled
from the low-risk group, 50% from the medium-risk
group, and 80% from the high-risk group.
This sampling procedure was performed before gener-
ating each validation dataset and resulted in validation
datasets that were half the size of the original datasets.
In contrast, no sampling of patients was performed
when generating the development datasets; all patients
were used.
The prognostic indices were approximately normally
distributed for all risk profiles and for both datasets.
There was slight skewness, particularly in the low and
medium risk profile datasets. For example, the (average)
skewness in the HCM datasets was 0.8 (low risk profile),
0.4 (medium) and 0.1 (high). There was a similar trend
in the breast cancer datasets, although the values were
lower. The variance was largest for the medium profile
datasets which was to be expected considering the sam-
pling scheme. This suggests that the medium profile
datasets contained more prognostic information than
the low and high profile datasets. Finally, there was
more prognostic information in the breast cancer data,
as evidenced by the wider range of the corresponding
prognostic indices.
Simulation results
Table 3 shows the mean values of the overall performance
measures over 5000 simulations for the breast cancer data,
for the four levels of censoring and three risk profiles. The
three summary measures based on predictive accuracy
(R2IBS, R
2
SH and R
2
S) produced very similar values and were
all unaffected by censoring. The values of these measures
were highest for the medium risk profile simulations,
where the patient characteristics were essentially the same
in the development and validation samples, and lowest for
the low risk profile simulations. Variability increased with
increasing censoring, as expected, and was highest for
R2IBS. This can clearly be seen in Fig. 2 which shows the
distribution of the values of the performance measures
over the 5000 simulations (a few negative values were
deleted to aid clarity). R2BS, evaluated at 3 years, was also
unaffected by censoring and achieved higher values in themedium risk profile simulations. R2BS also produced some
negative values (4%) when censoring was 80%. The two
measures based on explained variation (R2PM and R
2
D)
produced similar values that were twice as large as the
values obtained for R2IBS, R
2
SH and R
2
S. R
2
PM was unaffected
by censoring but R2D increased slightly as censoring
increased. The relationships between the various overall
performance measures are shown in Fig. 3 for the medium
risk profile scenario. In particular, there was excellent
agreement between the R2SH and R
2
S measures which
weakened as censoring increased (ρ = 0.54 for 80%
censoring). Also, there was good agreement between R2PM
and R2D which seemed little affected by censoring (ρ = 0.95).
Very similar relationships were seen for the low and high
risk scenarios (results not shown).
Table 4 shows the mean values of the discrimination
and calibration measures for the breast cancer data. The
Harrell and Uno c-indices were estimated twice, first
using all usable patient pairs (CH and CU) and second by
restricting the calculations by censoring times greater
than 3 years (CH(3) and CU(3)). For 0% censoring, the
CH and CGH mean values were very similar, and the CH
and CU estimates were identical by definition. CH tended
to increase as censoring increased, whereas CU and
particularly CGH were little affected. CGH was the least
variable of these three estimates. The variability in CH
and CU was similar except for 80% censoring where the
variability in CU was far larger (Fig. 4). The increased
variability was probably due to large values of the
weights caused by the high degree of censoring. The
mean value of CH(3) (and CU(3)) was slightly larger than
that for CH which suggests that the models were better
able to discriminate within the first 3 years compared to
across the whole follow-up period. Both CH(3) and
CU(3) were relatively stable with respect to censoring,
and the variability of both measures was similar. The
calibration slope and particular the D statistic showed a
slight tendency to increase with censoring. The relation-
ships between the discrimination measures are shown in
Fig. 5 for the medium risk profile scenario. In particu-
larly, there was reasonable agreement between the
concordance measures and D. The strong relationship
between CH and CH(3) for 80% censoring is explained by
the fact that there were few observed failure times above
3 years with this level of censoring. Very similar relation-
ships were seen for the low and high risk breast cancer
scenarios (results not shown).
The results for the overall performance measures for
the HCM data can be seen in Table 5 and Fig. 6. The
mean values were all lower than the corresponding
values for the breast cancer data. In particular, the
predictive accuracy values were considerably lower due
to the relatively low number of events (5%) that
occurred before 5 years. In addition there were many
Table 3 Mean (SD) of the overall performance measures for the breast cancer data over 5000 simulations
Profile Censoring R2IBS(3) R
2
SH(3) R
2
S(3) R
2
BS(3) R
2
PM R
2
D
Low 0% 0.099 (0.032) 0.100 (0.018) 0.101 (0.018) 0.128 (0.037) 0.232 (0.034) 0.225 (0.034)
Low 20% 0.098 (0.033) 0.100 (0.019) 0.101 (0.019) 0.128 (0.038) 0.232 (0.038) 0.228 (0.038)
Low 50% 0.099 (0.034) 0.101 (0.019) 0.101 (0.019) 0.129 (0.040) 0.234 (0.045) 0.238 (0.048)
Low 80% 0.098 (0.041) 0.100 (0.024) 0.099 (0.023) 0.127 (0.060) 0.235 (0.065) 0.255 (0.075)
Medium 0% 0.131 (0.032) 0.133 (0.018) 0.135 (0.018) 0.176 (0.039) 0.279 (0.035) 0.277 (0.036)
Medium 20% 0.133 (0.032) 0.135 (0.018) 0.135 (0.018) 0.177 (0.040) 0.280 (0.038) 0.280 (0.038)
Medium 50% 0.131 (0.034) 0.135 (0.019) 0.134 (0.019) 0.176 (0.045) 0.279 (0.046) 0.283 (0.047)
Medium 80% 0.130 (0.045) 0.133 (0.025) 0.131 (0.025) 0.176 (0.082) 0.281 (0.068) 0.292 (0.071)
High 0% 0.121 (0.028) 0.123 (0.015) 0.125 (0.015) 0.165 (0.035) 0.247 (0.035) 0.243 (0.034)
High 20% 0.121 (0.028) 0.124 (0.016) 0.124 (0.016) 0.165 (0.038) 0.247 (0.038) 0.242 (0.037)
High 50% 0.121 (0.031) 0.125 (0.016) 0.124 (0.017) 0.164 (0.046) 0.247 (0.047) 0.243 (0.046)
High 80% 0.120 (0.048) 0.121 (0.022) 0.120 (0.026) 0.168 (0.114) 0.250 (0.070) 0.252 (0.071)
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2
BS values (11 and 9% respectively).
R2D was affected by censoring in the low and medium
risk profile simulations which may be explained by
skewness in the prognostic index [6]. For example, the
prognostic index was most skewed in the low risk profile
HCM simulations, which is where greatest effect of
censoring was observed. The relationships between the
overall performance measures were similar, and often
slightly stronger, than those seen in the breast cancer
simulations (results not shown).Fig. 2 Box plots showing the distribution of the overall performance m
censoring (0, 20, 50 and 80%) for the breast cancer data over 5000 simThe results for the discrimination and calibration mea-
sures for the HCM data can be seen in Table 6 and Fig. 7.
As with the overall performance measures, the discrim-
ination values were all lower than the corresponding
values for the breast cancer data. CH was again badly
affected by censoring. In addition, D, like R2D, was also
affected by censoring in the low and medium risk profile
simulations. Also notable is the increased variability of
the CH(5) and CU(5) measures compared to their unre-
stricted counterparts. This again is due to the relativelyeasures for 3 risk profiles (low, medium and high) and 4 levels of
ulations
Fig. 3 Scatter plot showing the relationships between the overall performance measures for the breast cancer data with the medium risk
profile over 5000 simulations
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and the consequent low number of patient pairs used
to estimate both measures. Again, the relationships
between the discrimination measures were similar to
those seen in the breast cancer simulations (results
not shown). In particular, there was excellent agree-
ment between CGH and D (ρ = 0.99).
Discussion
The aim of this research was to review some of the
promising performance measures for evaluating predic-
tion models for survival outcomes, modify them if
necessary for use with external validation data, andTable 4 Mean (SD) of the discrimination and calibration measures f
Profile Censoring CH CU(τmax) CGH
Low 0% 0.667 (0.015) 0.667 (0.015) 0.667 (0.012
Low 20% 0.670 (0.018) 0.667 (0.016) 0.667 (0.014
Low 50% 0.679 (0.023) 0.668 (0.022) 0.668 (0.017
Low 80% 0.689 (0.039) 0.673 (0.060) 0.667 (0.024
Medium 0% 0.690 (0.015) 0.690 (0.015) 0.689 (0.013
Medium 20% 0.694 (0.017) 0.690 (0.015) 0.690 (0.014
Medium 50% 0.701 (0.022) 0.690 (0.021) 0.689 (0.017
Medium 80% 0.711 (0.037) 0.698 (0.056) 0.689 (0.024
High 0% 0.677 (0.015) 0.677 (0.015) 0.676 (0.013
High 20% 0.679 (0.017) 0.677 (0.016) 0.676 (0.014
High 50% 0.684 (0.023) 0.677 (0.021) 0.676 (0.018
High 80% 0.692 (0.038) 0.683 (0.058) 0.676 (0.026perform a simulation study based on two clinical datasets
in order to make practical recommendations.
Measures based on predictive accuracy quantify the
predictive ability of the prediction model, relative to a
null model with no predictors, on a percentage scale and
can be readily communicated to health researchers. The
measures investigated in this study (R2IBS, R
2
BS, R
2
SH and
R2S) may be estimated for any survival prediction model
provided that both the prognostic index and baseline
survival function are available, although R2SH also implicitly
assumes that the model is correctly specified [12]. If the
baseline survival function is not available, which is usually
the case in practice [6], then one approach might be toor the breast cancer data over 5000 simulations
CH(3) CU(3) D Cal. Slope
) 0.684 (0.028) 0.684 (0.028) 1.103 (0.107) 0.981 (0.108)
) 0.684 (0.029) 0.684 (0.029) 1.111 (0.121) 0.982 (0.116)
) 0.687 (0.030) 0.685 (0.029) 1.144 (0.152) 0.987 (0.136)
) 0.690 (0.040) 0.684 (0.040) 1.197 (0.243) 0.989 (0.190)
) 0.704 (0.023) 0.704 (0.023) 1.269 (0.113) 0.979 (0.101)
) 0.705 (0.024) 0.704 (0.024) 1.278 (0.123) 0.984 (0.107)
) 0.706 (0.026) 0.704 (0.026) 1.288 (0.152) 0.980 (0.126)
) 0.711 (0.037) 0.704 (0.037) 1.316 (0.231) 0.986 (0.177)
) 0.684 (0.021) 0.684 (0.021) 1.158 (0.108) 0.977 (0.108)
) 0.684 (0.022) 0.683 (0.021) 1.155 (0.118) 0.979 (0.116)
) 0.686 (0.025) 0.683 (0.024) 1.158 (0.148) 0.980 (0.139)
) 0.692 (0.038) 0.685 (0.042) 1.187 (0.230) 0.987 (0.198)
Fig. 4 Box plots showing the distribution of the concordance measures for 3 risk profiles (low, medium and high) and 4 levels of censoring
(0, 20, 50 and 80%) for the breast cancer data over 5000 simulations
Fig. 5 Scatter plot showing the relationships between the discrimination measures for the breast cancer data with the medium risk
profile over 5000 simulations
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Table 5 Mean (SD) of the overall performance measures for the HCM data over 5000 simulations
Profile Censoring R2IBS(5) R
2
SH (5) R
2
S (5) R
2
BS(5) R
2
PM R
2
D
Low 0% 0.013 (0.015) 0.013 (0.006) 0.014 (0.006) 0.020 (0.019) 0.173 (0.021) 0.166 (0.021)
Low 20% 0.013 (0.014) 0.013 (0.006) 0.013 (0.006) 0.020 (0.019) 0.173 (0.022) 0.173 (0.023)
Low 50% 0.014 (0.015) 0.013 (0.006) 0.013 (0.006) 0.020 (0.019) 0.174 (0.026) 0.184 (0.029)
Low 80% 0.014 (0.015) 0.014 (0.007) 0.014 (0.006) 0.020 (0.020) 0.174 (0.037) 0.201 (0.047)
Medium 0% 0.018 (0.014) 0.018 (0.006) 0.019 (0.006) 0.027 (0.019) 0.221 (0.022) 0.221 (0.023)
Medium 20% 0.018 (0.014) 0.018 (0.006) 0.019 (0.006) 0.027 (0.018) 0.221 (0.023) 0.226 (0.024)
Medium 50% 0.018 (0.014) 0.018 (0.006) 0.019 (0.006) 0.027 (0.019) 0.221 (0.028) 0.233 (0.031)
Medium 80% 0.018 (0.015) 0.018 (0.008) 0.019 (0.007) 0.027 (0.019) 0.222 (0.038) 0.241 (0.042)
High 0% 0.018 (0.013) 0.018 (0.005) 0.018 (0.005) 0.026 (0.017) 0.199 (0.022) 0.200 (0.022)
High 20% 0.018 (0.013) 0.018 (0.005) 0.018 (0.005) 0.027 (0.017) 0.199 (0.023) 0.201 (0.023)
High 50% 0.018 (0.013) 0.018 (0.006) 0.018 (0.005) 0.026 (0.017) 0.200 (0.028) 0.203 (0.029)
High 80% 0.018 (0.013) 0.018 (0.007) 0.018 (0.006) 0.026 (0.017) 0.201 (0.040) 0.206 (0.041)
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choice as the baseline survival function is rarely presented
in practice by model developers. An alternative, arguably
better, approach would be to estimate the baseline survival
function for the prediction model (with covariates), but
not the null model, using the development data. This
alternative approach was investigated in the case study
and produced very similar results (not shown). A negli-
gible difference in the baseline survival function is also
reported in [6] when it was estimated using developmentFig. 6 Box plots showing the distribution of the overall performance m
censoring (0, 20, 50and 80%) for the HCM data over 5000 simulationsand validation data separately. Similarly, for predic-
tions from a null model, which are required for these
measures, we suggest using the Kaplan-Meier estimate
from the validation data.
Again for these measures, a choice of time-point is
also required since the summary measures (R2IBS, R
2
SH
and R2S) are estimated over a specified range and R
2
BS is
estimated at a specified time-point. In practice, the
choice of time-point will be guided by the clinical
research question and the length of follow-up. Foreasures for 3 risk profiles (low, medium and high) and 4 levels of
Table 6 Mean (SD) of the discrimination and calibration measures for the HCM data over 5000 simulations
Profile Censoring CH CU(τmax) CGH CH(5) Cu(5) D Cal. Slope
Low 0% 0.645 (0.011) 0.645 (0.011) 0.645 (0.009) 0.675 (0.061) 0.675 (0.061) 0.911 (0.070) 0.983 (0.082)
Low 20% 0.649 (0.012) 0.645 (0.011) 0.645 (0.009) 0.676 (0.061) 0.676 (0.061) 0.934 (0.075) 0.986 (0.086)
Low 50% 0.656 (0.016) 0.645 (0.014) 0.645 (0.011) 0.676 (0.062) 0.676 (0.062) 0.971 (0.095) 0.989 (0.098)
Low 80% 0.666 (0.026) 0.649 (0.039) 0.645 (0.016) 0.676 (0.063) 0.676 (0.063) 1.025 (0.151) 0.988 (0.136)
Medium 0% 0.670 (0.010) 0.670 (0.010) 0.670 (0.009) 0.694 (0.049) 0.694 (0.049) 1.090 (0.072) 0.985 (0.075)
Medium 20% 0.674 (0.012) 0.670 (0.011) 0.670 (0.009) 0.695 (0.048) 0.695 (0.048) 1.105 (0.077) 0.986 (0.079)
Medium 50% 0.680 (0.015) 0.670 (0.013) 0.670 (0.011) 0.694 (0.049) 0.694 (0.049) 1.127 (0.097) 0.985 (0.091)
Medium 80% 0.688 (0.022) 0.675 (0.033) 0.670 (0.015) 0.695 (0.050) 0.695 (0.050) 1.153 (0.134) 0.989 (0.115)
High 0% 0.661 (0.011) 0.661 (0.011) 0.661 (0.009) 0.676 (0.043) 0.676 (0.043) 1.022 (0.070) 0.982 (0.079)
High 20% 0.663 (0.011) 0.661 (0.011) 0.661 (0.010) 0.677 (0.043) 0.677 (0.043) 1.025 (0.075) 0.983 (0.083)
High 50% 0.667 (0.015) 0.661 (0.013) 0.661 (0.011) 0.676 (0.043) 0.676 (0.043) 1.032 (0.092) 0.984 (0.097)
High 80% 0.672 (0.023) 0.664 (0.034) 0.661 (0.016) 0.676 (0.044) 0.676 (0.044) 1.042 (0.133) 0.987 (0.132)
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[4, 20]. The four predictive accuracy measures studied
were not affected by censoring in the simulation study.
In addition, the three summary measures (R2IBS, R
2
SH and
R2S) produced very similar values on average. However,
the variability of R2IBS was much greater than R
2
SH and R
2
S
which suggests that use of the latter two measures might
be preferred in practice if a summary measure is
required. Hielscher et al. compared two of these mea-
sures, R2IBS and R
2
SH, and had similar findings [12].Fig. 7 Box plots showing the distribution of the concordance measures for 3
and 80%) for the HCM data over 5000 simulationsThe measures based on explained variation (R2PM and
R2D) may be estimated for any proportional hazards
model provided that the prognostic index is available,
although we suggest that the prediction model is
re-calibrated to the validation data before calculation of
R2PM to ensure that the survival times in the validation
data are used in its calculation. Both measures provided
very similar values in our simulations. R2PM was robust
to censoring, but R2D tended to increase with censoring if
the prognostic index was skewed.risk profiles (low, medium and high) and 4 levels of censoring (0, 20, 50
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since the concept of correctly ranking patient pairs can
be readily communicated to health researchers [5]. CH
and CU can be estimated for any survival prediction
model that is able to rank patients. In addition, the
calculation of CU may also be restricted to a specified
range of time, which may be useful to match with
clinical aims or to compare concordance across different
datasets. The calculation of CH may also be restricted
though it is not clear how often this is done in practice
[37]. CGH has a similar interpretation to the other
concordance measures but requires that the model is
correctly specified. As with R2PM, we suggest that the
prediction model is re-calibrated to the validation data
before calculation of CGH to ensure that the survival
times in the validation data are used. Harrell’s CH, in its
unrestricted form, is probably the most used concord-
ance measure in practice [5]. However, it was affected by
censoring, which is a finding noted by others [16].
Specifically, CH tended to increase for moderate to high
levels of censoring, which is not an uncommon scenario
with medical data, and is therefore likely to give an over-
optimistic view of a prediction model’s discriminatory
ability. Therefore, it cannot be recommended in such
scenarios. In contrast, both CU and CGH were reasonably
stable in the presence of censoring. CGH was the less
variable of the two measures as a consequence of it
being model-based [16]. The restricted versions of CH
and CU were little affected by censoring but care needs
to be taken when selecting the time-point to ensure that
the time period contains a reasonable number of events.
The remaining discrimination measure D has an
appealing interpretation as it can be communicated
as a (log) relative risk between low and high risk
groups of patients. It requires that the proportional
hazards assumption holds and that the prognostic
index is normally distributed. As with R2D it may be
affected by censoring if the prognostic index is
skewed [27]. The sole calibration measure under
investigation, the calibration slope, was robust to
censoring. It assumes that the proportional hazards
assumption holds although more general approaches
are described by van Houwelingen [33, 38].
Conclusions
Harrell’s CH is routinely reported to assess discrimination
when survival prediction models are validated [5]. However,
based on our simulation results, we recommend that CU is
used instead to quantify concordance when there are
moderate levels of censoring. Alternatively, CGH could be
considered, especially if censoring is very high, but we
suggest that the prediction model is re-calibrated first. The
restricted version of CH may also be used provided that the
time-point is chosen carefully. We also recommend that Dis routinely reported to assess discrimination since it has an
appealing interpretation, although the distribution of the
prognostic index would need to be checked for
normality. ‘Overall performance’ measures are perhaps
under used in practice. Our recommendation would
be to use any of the predictive accuracy measures
and provide the corresponding predictive accuracy
curves. In particular, R2SH and R
2
S have relatively low
variability. The calibration slope is a useful measure
of calibration and recommended to report routinely.
In addition, one could investigate calibration graphically,
for example by comparing observed and predicted survival
curves for groups of patients [6]. Finally, we also recom-
mend to investigate the characteristics of the validation
data such as the level of censoring and the distribution of
the prognostic index derived in the validation setting
before choosing the performance measures.
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